UBS Knock-Out AMGN/ DE000UK9NFF3 /
2024-05-22 10:05:26 AM | Chg.0.000 | Bid10:05:26 AM | Ask10:05:26 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.770EUR | 0.00% | 0.770 Bid Size: 50,000 |
0.810 Ask Size: 50,000 |
Amgen Inc | 398.8731 USD | 2078-12-31 | Put |
GlobeNewswire
7:00 AM
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
05-21
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
05-21
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...
GlobeNewswire
05-15
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
05-14
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing Towards Global Dossier
GlobeNewswire
05-14
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Adv...
GlobeNewswire
05-13
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-09
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 ...
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination ...
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...